FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1498394002> ?p ?o ?g. }

• W1498394002 endingPage "95" @default.
• W1498394002 startingPage "4389" @default.
• W1498394002 abstract "p53 transgenic mice carrying a dominant negative mutation were crossed with Ink4A/Arf heterozygous-deficient mice to investigate whether there is a synergy between these two germ-line mutations in promoting carcinogen-induced lung tumor progression in mice. Mice with a p53 dominant negative mutation and Ink4A/Arf heterozygous deficiency exhibited >20-fold increase in tumor volume compared with approximately 4-fold increase in Ink4A/Arf heterozygous-deficient mice and a 9-fold increase in mice with only the p53 dominant negative mutation. The effect of Ink4A/Arf heterozygous deficiency on lung tumor progression occurred late in the carcinogenesis process (>30 weeks after carcinogen treatment). In addition, most of the lung tumors (approximately 80%) from mice with a p53 mutation and deletion of Ink4A/Arf were lung adenocarcinomas. In contrast, lung adenocarcinomas were seen in <10% of the lung tumors from the wild-type mice and approximately 50% of the lung tumors from Ink4a/Arf heterozygous-deficient or p53 mutant mice. These results indicate a significant synergistic interaction between the presence of a mutant p53 transgene and the Ink4A/Arf deletion during lung tumor progression (P < 0.01). The usefulness of this new mouse model in lung cancer chemoprevention was examined. The chemopreventive efficacy of budesonide was examined in wild-type mice, mice with Ink4A/Arf heterozygous deficiency, mice with a mutation in the p53 gene, or mice with both a mutation in the p53 gene and deletion in the Ink4A/Arf locus. Mice treated with budesonide displayed an average of 90% inhibition of lung tumor progression in a standard 18-week chemoprevention assay, regardless of p53 and/or Ink4A/Arf status. However, the efficacy of budesonide against lung tumor progression decreased from 94 to 77% (P = 0.07) in mice with alterations in both p53 and Ink4A/Arf in a 40-week chemoprevention assay. Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively. Thus, mutant mice with alterations in p53 and/or Ink4A/Arf exhibited a significant resistance to chemoprevention by budesonide. Because p53 and Ink4a/Arf mutations are the most prevalent mutations in human lung cancers, the effectiveness of chemopreventive agents on the mutant A/J mice containing alterations with p53 and Ink4a/Arf is the best preclinical estimate of their efficacy in humans. Thus, the mutant A/J mouse model should prove useful for chemoprevention studies." @default.
• W1498394002 created "2016-06-24" @default.
• W1498394002 creator A5009548740 @default.
• W1498394002 creator A5010301838 @default.
• W1498394002 creator A5014024059 @default.
• W1498394002 creator A5031224691 @default.
• W1498394002 creator A5069890795 @default.
• W1498394002 date "2003-08-01" @default.
• W1498394002 modified "2023-10-16" @default.
• W1498394002 title "Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice." @default.
• W1498394002 cites W143753117 @default.
• W1498394002 cites W1488876341 @default.
• W1498394002 cites W1502430583 @default.
• W1498394002 cites W1560780012 @default.
• W1498394002 cites W1580797218 @default.
• W1498394002 cites W1606506184 @default.
• W1498394002 cites W1758507682 @default.
• W1498394002 cites W1963756534 @default.
• W1498394002 cites W1968813488 @default.
• W1498394002 cites W1977706798 @default.
• W1498394002 cites W1983348452 @default.
• W1498394002 cites W1983751803 @default.
• W1498394002 cites W1986955994 @default.
• W1498394002 cites W1990386577 @default.
• W1498394002 cites W1995978517 @default.
• W1498394002 cites W2004567377 @default.
• W1498394002 cites W2023068350 @default.
• W1498394002 cites W2028210102 @default.
• W1498394002 cites W2028779612 @default.
• W1498394002 cites W2036966657 @default.
• W1498394002 cites W2039463309 @default.
• W1498394002 cites W2043141000 @default.
• W1498394002 cites W2046958356 @default.
• W1498394002 cites W2048649566 @default.
• W1498394002 cites W2049085719 @default.
• W1498394002 cites W2056166014 @default.
• W1498394002 cites W2066848701 @default.
• W1498394002 cites W2071440441 @default.
• W1498394002 cites W2073651612 @default.
• W1498394002 cites W2084891010 @default.
• W1498394002 cites W2085588237 @default.
• W1498394002 cites W2088237419 @default.
• W1498394002 cites W2088740611 @default.
• W1498394002 cites W2097469649 @default.
• W1498394002 cites W2105151355 @default.
• W1498394002 cites W2114247191 @default.
• W1498394002 cites W2126679757 @default.
• W1498394002 cites W2131821779 @default.
• W1498394002 cites W2146587451 @default.
• W1498394002 cites W2147558648 @default.
• W1498394002 cites W2147648567 @default.
• W1498394002 cites W2150230220 @default.
• W1498394002 cites W2169473586 @default.
• W1498394002 cites W2174418452 @default.
• W1498394002 cites W2406266692 @default.
• W1498394002 cites W2410672400 @default.
• W1498394002 cites W2109317141 @default.
• W1498394002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12907609" @default.
• W1498394002 hasPublicationYear "2003" @default.
• W1498394002 type Work @default.
• W1498394002 sameAs 1498394002 @default.
• W1498394002 citedByCount "26" @default.
• W1498394002 countsByYear W14983940022013 @default.
• W1498394002 countsByYear W14983940022017 @default.
• W1498394002 countsByYear W14983940022018 @default.
• W1498394002 countsByYear W14983940022019 @default.
• W1498394002 countsByYear W14983940022021 @default.
• W1498394002 countsByYear W14983940022022 @default.
• W1498394002 crossrefType "journal-article" @default.
• W1498394002 hasAuthorship W1498394002A5009548740 @default.
• W1498394002 hasAuthorship W1498394002A5010301838 @default.
• W1498394002 hasAuthorship W1498394002A5014024059 @default.
• W1498394002 hasAuthorship W1498394002A5031224691 @default.
• W1498394002 hasAuthorship W1498394002A5069890795 @default.
• W1498394002 hasConcept C102230213 @default.
• W1498394002 hasConcept C104317684 @default.
• W1498394002 hasConcept C121608353 @default.
• W1498394002 hasConcept C126322002 @default.
• W1498394002 hasConcept C141035611 @default.
• W1498394002 hasConcept C142724271 @default.
• W1498394002 hasConcept C143065580 @default.
• W1498394002 hasConcept C203014093 @default.
• W1498394002 hasConcept C207583985 @default.
• W1498394002 hasConcept C2776256026 @default.
• W1498394002 hasConcept C2777714996 @default.
• W1498394002 hasConcept C2777928079 @default.
• W1498394002 hasConcept C2778264664 @default.
• W1498394002 hasConcept C2779256057 @default.
• W1498394002 hasConcept C502942594 @default.
• W1498394002 hasConcept C54355233 @default.
• W1498394002 hasConcept C555283112 @default.
• W1498394002 hasConcept C71924100 @default.
• W1498394002 hasConcept C86803240 @default.
• W1498394002 hasConceptScore W1498394002C102230213 @default.
• W1498394002 hasConceptScore W1498394002C104317684 @default.
• W1498394002 hasConceptScore W1498394002C121608353 @default.
• W1498394002 hasConceptScore W1498394002C126322002 @default.
• W1498394002 hasConceptScore W1498394002C141035611 @default.

• next